[{"orgOrder":0,"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Genfa Medica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Genfa Medica \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"Genfa Medica \/ MediWound"}]

Find Clinical Drug Pipeline Developments & Deals by Genfa Medica

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hospitalar
                          Not Confirmed
                          Hospitalar
                          Not Confirmed

                          Details : MediWound granted GENFA MEDICA SA right to distribute NexoBrid® in France and Switzerland and Specialty Therapeutics the right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          April 05, 2020

                          Lead Product(s) : Bromelain

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : MediWound

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank